Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

PEPtide-based Therapy for recurrent Ovarian Cancer

Project description

Preventing ovarian cancer recurrence

Ovarian cancer recurrence remains a major challenge in oncology, with relapse rates exceeding 80 % in advanced-stage cases. Current therapies target broad DNA repair and signalling mechanisms; however, their limited specificity causes significant side effects. The ERC-funded PEPTOC project proposes a paradigm shift from treating recurrence to preventing it by targeting the cellular pathways underlying chemotherapy resistance. Researchers will validate PEPTOC in preclinical in vivo models and secure intellectual property before proceeding to commercialisation. To facilitate translation in the clinic, the project will engage with clinicians, patients and pharmaceutical stakeholders. If successful, PEPTOC could deliver the first preventive therapeutic option for ovarian cancer recurrence.

Objective

Ovarian cancer recurrence after complete clinical response is a major challenge in gynecologic oncology. Recurrence occurs in nearly 25% of early-stage cases and in more than 80% of advanced-stage cases. Current targeted therapies for the treatment of ovarian cancer relapse are still in Phase II clinical trials and, while these therapies represent significant advances in cancer treatment, they target broad inhibitory mechanisms that affect DNA repair and signaling pathways in a variety of cell types, which lead to significant side-effects.
To address the critical challenge of recurrent ovarian cancer, PEPTOC’s solution shifts the paradigm from treating recurrence to preventing it. By strategically targeting the cellular pathways involved in chemotherapy resistance, PEPTOC offers a preventive approach to avoid ovarian cancer recurrence.
This ERC Proof of Concept project aims to:
1) Perform preclinical validation of PEPTOC in an in vivo model.
2) Secure intellectual property and define the commercialization pathway.
3) Develop and implement a comprehensive business strategy.
Taken together, the objectives of PEPTOC will pursue the steps necessary to develop a viable therapeutic option: ensure that the therapy is both safe and effective in vivo, protect intellectual property and define the commercialization pathway (spinout company and strategic partnerships, if needed), and engage with relevant stakeholders through a series of activities, including workshops with oncologists, focus groups with patients, and meetings with pharmaceutical representatives and investors at industry events. To guide these efforts, we will rely on the expertise of Key Opinion Leaders serving on an Advisory Board to ensure that PEPTOC’s development is strategically aligned with market needs. If successful, PEPTOC would represent a breakthrough innovation in oncology, providing a first-of-its-kind solution for the prevention of ovarian cancer recurrence.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

UNIVERSIDADE DA CORUNA
Net EU contribution
€ 150 000,00
Address
CALLE DE LA MAESTRANZA 9
15001 La Coruna
Spain
Region
Noroeste Galicia A Coruña
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)